Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Randomized Controlled Trial Comparing Tocilizumab to Anti-TNF Treatment and Discovery of Biomarkers for Treatment Selection in Rheumatoid Arthritis Patients With Inadequate Response to a First Anti-TNF

Trial Profile

Open-label, Randomized Controlled Trial Comparing Tocilizumab to Anti-TNF Treatment and Discovery of Biomarkers for Treatment Selection in Rheumatoid Arthritis Patients With Inadequate Response to a First Anti-TNF

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Tocilizumab (Primary) ; Tocilizumab (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RAFTING
  • Most Recent Events

    • 07 Jan 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2020.
    • 27 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 23 Feb 2018 Planned End Date changed from 1 Sep 2021 to 1 Oct 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top